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ScienceDirectCancer development involves the stepwise accumulation of
genetic lesions that overcome the normal regulatory pathways
that prevent unconstrained cell division and tissue growth.
Identification of the genetic changes that cause cancer has
long been the subject of intensive study, leading to the
identification of several RNA-binding proteins (RBPs) linked to
cancer. Cross-reference of the complement of RBPs recently
identified by RNA interactome capture with cancer-associated
genes and biological processes led to the identification of
a set of 411 proteins with potential implications in cancer
biology. These involve a broad spectrum of cellular processes
including response to stress, metabolism and cell adhesion.
Future studies should aim to understand these proteins and
their connection to cancer from an RNA-centred perspective,
holding the promise of new mechanistic understanding of
cancer formation and novel approaches to diagnosis and
treatment.
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Introduction
Genetic and epigenetic mutations can lead to dysregula-
tion of the cellular mechanisms controlling cell fate,
ultimately causing cancer. The hallmarks of cancer
include uncontrolled cell proliferation in the absence of
external cues, resistance to cell death, evasion of growth
suppressors and the immune system, metabolic repro-
gramming, tissue invasion and metastasis, and sustainedCurrent Opinion in Genetics & Development 2018, 48:112–120 angiogenesis [1]. Identification of causal genetic variants
in cancer has long been the subject of intensive study, and
a number of these have been mapped to RNA-binding
proteins (RBPs). RBPs assemble dynamic complexes
with RNA, termed ribonucleoproteins (RNPs), that
mediate virtually every stage of the RNA lifecycle [2].
Cancer-conducive mutations and mis-expression of RBPs
affect most if not all steps of RNA metabolism, including
RNA splicing (e.g. SRSF2) [3], 30 end processing (e.g.
CPEB1) [4,5], editing (e.g. ADAR1) [6,7], stability (e.g.
ZFP36) [8], storage and localisation (e.g. IMP/IGF2BP
proteins) [9], translation (e.g. eIF4E) [10], and biogenesis
of small RNAs such as miRNAs (e.g. AGO2, LIN28) [11].
Alterations of RNA metabolism due to RBP dysfunction
can cause global changes in the transcriptome and prote-
ome of the cell that can affect cell growth, proliferation,
invasion and death. Most of the RBPs studied in the
context of cancer are bona fide, canonical RBPs charac-
terised by the presence of canonical RNA-binding
domains (RBDs) such as RNA-recognition motifs
(RRMs) [12]. The functions of such canonical RBPs in
cancer aetiology have been recently reviewed elsewhere
[13,14–16]. However, studies over the past three decades
have identified many RBPs harbouring non-canonical
RBDs, whose roles in cancer remain largely unknown.
The complement of non-canonical RBPs was largely
expanded with the recently developed proteome-wide
approaches for unbiased identification of RBPs, uncover-
ing hundreds of proteins lacking classical RBDs endowed
with RNA-binding activity [17,18]. Amongst many other
diverse molecular functions, these non-canonical or unor-
thodox RBPs include cell cycle regulators, metabolic
enzymes, protein scaffolds and antiviral factors. In this
review, we aim to highlight the emerging roles of non-
canonical RBPs in cancer.
Identifying cancer-linked RBPs
To systematically determine the complement of RBPs
with potential roles in cancer, we compared the census of
human RBPs collected in system-wide studies by RNA
interactome capture (RNA-IC) [19] and RBDmap [20]
with cancer-associated proteins annotated in the Cata-
logue of Somatic Mutations in Cancer (COSMIC) cancer
gene census list [21], Online Mendelian Inheritance in
Man (OMIM) [22], or related processes in Gene Ontology
(GO) [23]. RNA-IC employs ultraviolet crosslinking,
oligo (dT) capture and mass spectrometry to identify
RBPs [17,18]; RBDmap extends this protocol, utilisingwww.sciencedirect.com
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within RBPs engaged in the interaction with RNA [20].
Comparison of the RNA-bound proteome with cancer
proteins resulted in the identification of 696 RBPs with
potential implications in cancer biology (Figure 1, Table 1
and Supplementary Table 1). Seventy-three of these
RBPs were present in COSMIC, 435 in OMIM, and
477 were annotated by a GO term related to cancer.
The fact that half the RNA-bound proteome is related
here to cancer highlights the importance of RBPs in cell-
fate decisions. Splicing and translation emerge as pre-
dominant processes for cancer-related RBPs (Figure 1a).
Additionally, functions commonly associated with cancer,
including metabolic remodelling, cell adhesion, and inter-
feron response, are also observed (Figure 1a). Strikingly,
the set of cancer-related RBPs includes a similar propor-
tion of proteins harbouring well-established RBDs
(40.9%) and proteins lacking a recognisable RBD
(59.1%) (Figure 1b). Protein-protein interaction domains
such as ARM and WD40, and enzymatic cores such as P-
loop-NTPase, kinase-like and thioredoxin domains,
emerged as predominant signatures amongst unorthodox,
cancer-related RBPs (Figure 1c). Highlighting the links
of unorthodox RBPs to cancer, numerous cancer-related
mutations were identified throughout the sequence of
these proteins, including missense mutations, frameshifts
and premature stop codons (Figure 2 and Supplementary
Figures 1–3). Some of these mutations overlap with
proteins’ non-canonical RBDs (uncovered by RBDmap
[20]), invoking potential effects on RNA binding.
Below, we have selected a few families of these non-
canonical cancer-linked RBPs for further discussion.
Chaperones and protein scaffolds
Heat shock proteins (HSPs) are highly conserved molec-
ular chaperones that play important roles in protein
synthesis, localisation and degradation, whilst preventing
the accumulation of potentially pathogenic protein aggre-
gates. HSPs confer key cytoprotective effects to cells
under physiological stresses, facilitating cell survival.
HSP overexpression has been observed in a range of
cancers, where their cytoprotective and anti-apoptotic
effects are exploited to aid tumour growth, disease pro-
gression and metastasis [24]. HSP substrates include
proteins involved in key oncogenic signalling pathways.
Accordingly, the utility of HSP inhibitors in cancer ther-
apy is under extensive investigation, due in part to their
ability to target multiple proteins and upstream compo-
nents of tumour-associated pathways [25].
Several HSPs have been consistently classified as RBPs
by RNA-IC and RBDmap, including HSP90, HSP70,(Figure 1 Legend) RNA-binding proteins linked to cancer. (a) STRING [61] 
with links to cancer based on annotations in COSMIC, OMIM, and GO (see
showing breakdown of cancer-linked RBPs by RBD classification (i.e. class
cloud of domains present in unorthodox cancer-linked RBPs. Size indicates
Current Opinion in Genetics & Development 2018, 48:112–120 HSP60, HSP40 and HSP27 protein family members
[19,20] (Supplementary Table 1 and Supplementary
Figure 1). For example, HSP90aa1 is classified as canoni-
cal RBP here due to the presence of the Ribosomal S5
D2-type fold (residues 292–547). However, RBDmap
assigns the RNA-binding activity to the non-canonical
HSP90 domain and this is consistent across protein homo-
logues (Figure 2a). HSP90aa1 is upregulated in diffuse
large B cell lymphoma (DLBCL), along with the key
oncoprotein and transcriptional repressor BCL6.
HSP90aa1 upregulates both mRNA and protein levels
of BCL6 in vitro, and HSP90 inhibition can induce
antitumour effects in BCL6 positive DLBCL mouse
models [26].
In addition to HSP90, RBDmap identified high confi-
dence RNA-binding sites within the heat shock domains
of HSP70 and HSP27, which are conserved across homol-
ogous proteins [20]. This conservation suggests that
RNA-binding activity is a shared property among HSPs.
Strikingly, in vitro experiments show that certain HSPs
can bind AU-rich elements (ARE) in the 30-UTR of their
target mRNAs, mediating RNA decay [27]. RNA binding
appears to be independent of chaperone and ATPase
activities, at least for HSP70 [28]. HSPs play key roles in
RNA metabolism, including miRNA loading in the RNA-
induced silencing complex (RISC) [29] and folding of
nascent polypeptides concomitantly to ribosome’s activ-
ity [30]. miRNA and ribosomal activities are central in the
regulation of the cellular proteome, invoking potential
implications of RNA metabolism in the function of HSPs
in cancer development.
Protein–protein interaction domains have been identified
as novel RNA-binding sites in unorthodox RBPs [20].
This is the case in four out of seven members of YWHA
protein family, namely YWHAG, YWHAE, YWHAB and
YWHAZ [19,20], all of which have described links with
cancer or related pathways in the literature [31,32] (Sup-
plementary Table 1 and Supplementary Figure 2).
YWHA proteins bind serine/threonine phosphorylation
motifs in target proteins, thus regulating their activity,
localisation, post-translational modification status and
interactions. Recent studies proposed that YWHA family
harbours chaperone-like activities, preventing protein
aggregation, assisting HSPs in protein refolding, and
clearing misfolded proteins [33]. YWHA proteins are
therefore able to regulate a vast number of proteins
involved in key cellular processes, with implications for
tumorigenesis and cancer progression, such as cell cycle
progression and arrest, [34], apoptosis [35] and EMT [36],
along with key oncoproteins, such as p53 [37], andnetwork showing connections between RNA-binding proteins (RBPs)
 main text). Main network hubs are highlighted. (b) Sunburst graph
ical or non-canonical) and source of cancer-link information. (c) Word
 relative prevalence.
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Table 1
Selected unorthodox cancer-linked RBPs
Gene symbol Function(s) RBDmap Cancer resources Cancers
CDKN2A Alternative transcripts. Cell cycle arrest and
tumour suppressor functions.
 COSMIC, OMIM, GO Melanoma, pancreatic and multiple
cancers, familial malignant
melanoma
CLTC Component of clathrin-coated vesicles and
pits, involved in intracellular vesicle transport.
 COSMIC, OMIM, GO ALCL, renal
IDH1 Cytosolic and peroxisomal NADP-dependent
isocitrate dehydrogenase.
 COSMIC, OMIM, GO Glioblastoma
EIF3E Subunit of eIF3 complex. Role in translation
initiation.
 COSMIC, OMIM, GO Colorectal
JUN Component of API-1 complex transcription
factor.
 COSMIC, OMIM, GO Sarcoma
MYH9 Heavy chain component of nonmuscle myosin
II. Actin cytoskeleton binding and remodelling.
 COSMIC, OMIM, GO ALCL
ATP1A1 Catalytic subunit of Na(+), K(+) ATPase.
Generates plasma membrane electrochemical
gradient.
+ COSMIC, OMIM, GO Adrenal aldosterone producing
adenoma
NPM1 Nucleolar-nuclear-cytoplasmic shuttling
protein. Multiple functions including histone
and protein chaperone.
+ COSMIC, OMIM, GO NHL, APL, AML
POU5F1 POUhomeodomain-containing transcription
factor. Role in embryonic development and
stem cell pluripotency.
 COSMIC, OMIM, GO Sarcoma
RPL5 Ribosomal protein component of 60S
ribosome. Binds 5S rRNA to form 5S RNP,
transports to nucleolus for ribosomal assembly.
+ COSMIC, OMIM, GO T-ALL
TFRC Cell surface receptor mediating iron uptake via
receptor-mediated endocytosis.
 COSMIC, OMIM, GO NHL
TPR Structural component of nuclear pore complex,
crucial for nucleocytoplasmic transport.
 COSMIC, OMIM, GO Papillary thyroid, NSCLC
EZR Intermediate linking plasma membrane and
cytoplasm. Key for cell adhesion, migration,
structural stability and plasma membrane
structures.
 COSMIC, OMIM, GO NSCLC
YWHAE Adapter protein. Role in signal transduction/
signalling pathways, by binding multiple protein
partners.
 COSMIC, OMIM, GO Endometrial stromal sarcoma
DEK Role in chromatin organisation and splice site
selection during pre-mRNA processing.
 COSMIC, OMIM, GO AML
CALR Major calcium binding storage protein and
molecular chaperone in ER lumen
 COSMIC, OMIM, GO Myeloproliferative neoplasms,
myelodysplastic syndromes
HIST1H4I Involved in nucleosome formation and
organisation.
+ COSMIC, OMIM, GO NHL
PSIP1 Transcriptional coactivator.  COSMIC, OMIM AML
SF3B1 Mediates formation and anchoring of U2
snRNP to pre-mRNA upstream of intronic
branch sites.
+ COSMIC, OMIM Myelodysplastic syndromes
HLA-A Member of the HLA class I heavy chain
paralogues. Presents peptides derived from ER
lumen to the immune system.
 COSMIC, OMIM Spitzoid tumour
MYO5A Myosin 5 heavy chain member. Actin-based
motor protein involved in spindle pole assembly
and vesicle/mRNA transport.
 COSMIC, OMIM Spitzoid tumour
KMT2C Histone methyltransferase, specifcally
methylating H3 Lys-4 (epigenetic mark
associated with transcriptional activation)
 COSMIC, OMIM Medulloblastoma
TOP1 Alters DNA topology during transcription and
replication. Transiently cleaves and rejoins DNA
strands.
 COSMIC, OMIM AML
PHF6 Proposed role in transcription and/or chromatin
remodelling.
 COSMIC, OMIM ETP ALL
APOBEC3B Cytidine deaminase with role in retrovirus
replication and retrotransposon movement
inhibition.
 COSMIC, OMIM Breast cancer
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Table 1 (Continued )
Gene symbol Function(s) RBDmap Cancer resources Cancers
THRAP3 Component of spliceosome, involved in pre-
mRNA splicing and mRNA decay. Potential role
as transcriptional coactivator.
 COSMIC, OMIM Aneurysmal bone cyst
SND1 Transcriptional coactivator. Part of the RISC
complex. Roles in RNA editing, mRNA splicing
and stability.
+ COSMIC, GO Pancreas acinar carcinoma
KTN1 Integral ER protein. Binds kinesin, suggesting
role in intracellular vesicle/organelle mobility.
 COSMIC, GO Papillary thyroid
Candidate unorthodox RBPs that are present in at least two cancer resources (COSMIC cancer gene census, OMIM and GO), and are identified as
RBPs in more than two independent datasets (RBDmap or RNA-IC), are listed here. The complete list, together with additional analyses are available
in Supplementary Table 1 (ALCL = anaplastic large cell leukaemia, NHL = non-Hodgkin lymphoma, APL = acute promyelocytic leukaemia,
AML = acute myelogenous leukaemia, T-ALL = T-cell acute lymphoblastic leukaemia, NSCLC = non-small cell lung cancer, ETP ALL = early T-
cell precursor acute lymphoblastic leukaemia).components of oncogenic pathways [31,38,39]. YWHAB,
YWHAG and YWHAZ harbour a conserved RBD within
the 14-3-3 domain [20] overlapping with partially disor-
dered regions. Owing to the highly conserved nature of
these proteins, it is expected that YWHAE would bind
RNA as well, and indeed RNA binding is seen in the
YWHAE 14-3-3 domain in mouse (Supplementary
Table 1) [40]. The 14-3-3 domain consists of several
alpha helices, which form the amphipathic protein-inter-
acting groove, and include regions of charged and polar
amino acids (helices 3 and 5) and hydrophobic amino
acids (helices 7 and 9) [41], which provide suitable
potential RNA-binding interfaces. The role of RNA
binding in YWHA family function and its implications
in cancer development deserve further study.
Metabolic enzymes
Metabolic reprogramming is an emerging hallmark of
cancer [1], required to meet the increased energetic
and biosynthetic demands of rapidly proliferating and
dividing tumour cells. The RNA-bound proteome is
populated by many metabolic enzymes, which reinforces
and expands previous in vitro and in vivo data showing
that several enzymes of the intermediate metabolism
‘moonlight’ as RBPs and provide a new regulatory layer
between metabolism and gene expression [42,43]. For
example, the isocitrate dehydrogenase enzymes IDH1
and IDH2 function as RBPs [19,20], and are strongly
linked to cancer. IDH enzymes catalyse the reversible
conversion of isocitrate and NADP+ to a-ketoglutarate
(a-KG) and NADPH, a key process in the tricarboxylic
acid (TCA) cycle, lipid biosynthesis and NADPH pro-
duction. IDH2 binds RNA via the dehydrogenase
domain, as has been observed with other metabolic
enzymes [20,43] (Figure 2b). This region is also con-
served in IDH1, and indeed shows RNA binding activity
in mouse (Supplementary Table 1) [40]. How IDH1/2
RNA-binding activity influences its biological activity is
not known. However, mechanisms determined for other
moonlighting enzymes offer some possible clues.Current Opinion in Genetics & Development 2018, 48:112–120 Aconitase 1 (ACO1, also known as iron regulatory protein
1 (IRP1)) assembles with an iron–sulphur [Fe–S] cluster
under normal iron levels, forming the catalytically active
protein. However, under low iron concentrations [Fe–S]
is no longer available, causing ACO1 to remain as an
apoprotein. In this state, ACO1 binds the 50 and 30 UTRs
of mRNAs involved in iron homeostasis and regulates
their fate [42]. RNA binding and catalytic activity are
mutually exclusive functions that are actually linked to
different protein conformations [44]. Another RNA-bind-
ing metabolic enzyme is thymidylate synthase (TYMS), a
key target of cancer therapy that binds its own RNA in the
absence of its substrate. This unusual binding of the
enzyme to its mRNA inhibits its translation initiation
[45] thus providing a negative feedback loop that regu-
lates the level of the enzyme. TYMS also binds the RNAs
of the key tumour suppressor p53 and the key oncogene c-
myc [46,47], suggesting additional possible regulatory
roles in cancer development. Substrate (or cofactor)-
dependent regulation of protein levels (TYMS) or activity
(ACO1) offers a high degree of functional plasticity,
allowing rapid responses to alterations in the metabolic
state of the cell. Whether IDH1/2 follows a similar
strategy to ACO1 or TYMS, and whether it plays key
roles in cancer development will be important to explore.
IDH enzymes have well established roles in glioma,
secondary glioblastoma and acute myeloid leukaemia
(AML). The mechanistic role of IDH in these cancers
has been determined by analysing point mutations at
specific arginine residues (residues R132 and R172/
R140 in IDH1 and IDH2, respectively — Figure 2b) that
disrupt catalytic activity, resulting in neomorphic enzy-
matic activity, and the subsequent accumulation of 2-
hydroxyglutarate (D-2HG) from the reduction of a-KG.
This metabolic imbalance causes hypermethylation at
CG-rich DNA sequences (CpG islands), as D-2HG is
able to competitively inhibit a-KG dependent dioxy-
genases, such as DNA and histone demethylases. These
epigenetic lesions result in significant alterations of gene
expression [48–50]. Other lines of evidence have linkedwww.sciencedirect.com
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Figure 2
Examples of unorthodox cancer-linked RBPs. Architecture of (a) RNA-binding HSP90 proteins (b) IDH proteins 1 and 2 (c) the three ERM proteins.
Lollipops indicate the cancer-associated mutations available in the ICGC data portal [62], black boxes represent Pfam-annotated [63] protein
domains, red and orange boxes map the high-confidence and candidate RNA-binding sites reported by RBDmap [20], respectively, and green
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NADPH levels, which in turn leads to increased suscep-
tibility to reactive oxygen and nitrogen species, due to
lack of reduced antioxidant enzymes. This renders cells
vulnerable to ROS and oxidative DNA damage, which
can result in further accumulation of cancer-promoting
genetic lesions [51]. However, not all IDH mutations
observed in cancer impact catalytic activity, with other
observed IDH mutations (Figure 2b) resulting in loss of
function, overexpression or having no impact on WT
catalytic activity [49,52]. Knowing that TYMS auto-reg-
ulates its protein levels through interaction with its own
RNA [45], it is a sensible hypothesis that IDH may follow
a similar strategy, and that dysregulation of its RNA-
binding activity may result in altered IDH levels. This
possibility should be explored in the future.
In addition to IDH1/2, ACO1, and TYMS, thioredoxin-
domain containing antioxidant enzymes thioredoxin
(TXN) and glutaredoxin 3 (GLRX3), along with catalase
(CAT), peroxiredoxin 1 and 3 (PRDX1/PRDX3), were
identified as candidate cancer-associated RBPs (Supple-
mentary Figure 3), providing a potentially interesting link
between antioxidant metabolism, RNA binding and
cancer.
ERM proteins
All three members of the ezrin-radixin-moesin (ERM)
protein family were identified as RBPs by RNA-IC
[19,20] (Figure 2c and Supplementary Table 1). The
ERM proteins mediate interactions between the actin
cytoskeleton and plasma membrane, playing a key role in
the organisation of specialised membrane structures,
adhesion sites and cell junctions. Additionally, the
ERM proteins facilitate signal transduction between
intracellular and extracellular compartments, with roles
in adhesion and migration [53]. The ERM proteins are
suggested to influence cancer progression, including inva-
sion, EMT and metastasis, due to these functions in cell
adhesion and migration. Mislocalisation or altered ERM
expression can also influence receptor complex formation,
thus impacting signal transduction, including key onco-
genic pathways such as PI3K/Akt and Wnt/b-catenin
pathways [54]. RBDmap in human cells identified
RNA-binding activity in a disordered region within the
ERM domain in moesin and radixin [20]. Furthermore,
the same protein regions in the three ERM proteins were
reported by RBDmap to bind RNA in mouse, suggesting
conservation of this function across mammals [40]. Inter-
estingly, regulation of ERM proteins by a piRNA-like(Figure 2 Legend Continued) boxes indicate regions which are predicted t
mutated residues in IDH1 and IDH2 proteins with established links to sever
of reported mutations in parentheses.
Current Opinion in Genetics & Development 2018, 48:112–120 species has been observed in non-small cell lung cancer
lines, but not in normal lung bronchial epithelial lines
[55]. This highlights the potential role of RNA in the
regulation of protein’s function in pathological condi-
tions. The role of RNA-ERM interactions in cytoskeletal
configuration, cell adhesion and migration should be
studied in the future in the context of cancer
development.
Outlook
Recently developed global approaches for identification
of RBPs have uncovered a new universe of RNA-binding
activities, many of which have been linked to tumorigen-
esis, cancer progression, invasion and metastasis. We have
provided here an overview of the diversity of non-canon-
ical RBPs and their potential links with oncogenesis.
However, the precise roles of most of these unorthodox
RBPs in cancer, and the relevance of their RNA-binding
activities, remain to be elucidated. In this review, we have
limited our discussion to human RBPs that have been
experimentally identified by RNA-IC and RBDmap.
However, the task of uncovering the cancer-related
RNA-binding proteome is by no means complete. Other
in silico, in vitro and in vivo approaches for identification of
RBPs and RBDs have recently been developed 7
[17,18,20,56,57,58,59,60], with advantages and disad-
vantages over RNA-IC and RBDmap. For example, while
RNA-IC and RBDmap offer high specificity in the iden-
tification of RBPs, they are limited to polyadenylated
RNA. Some of the alternative approaches do not rely on
oligo(dT) capture, opening the possibility to identify
RBPs with specificity for non-polyadenylated RNA. In
the future, the combination of different RNA-binding
and cancer mutation data sources will help expand our
knowledge of RBPs and their links to cancer. There is
certainly interesting future work to elucidate the roles of
novel and non-canonical RBPs in the development and
progression of cancer. In the longer term, studying the
RNA biology of non-canonical mRNA binding proteins is
likely to lead to new avenues for treatments of specific
cancers.
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